Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist.

NCT02161757 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT02161757
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02161757 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Study to Evaluate the Efficacy and Safety of Tralokinumab in Adults and Adolescents With Asthma Inadequately Controlled on Inhaled Corticosteroid Plus Long-Acting β2-Agonist.
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
June 13, 2014
Completion date
July 18, 2017
Enrollment
1,207 (actual)
Sites
243

Conditions

As the registry lists them; a condition with its own page is linked.

uncontrolled asthma